Pinned Tweet
Caring for a person with type 2 diabetes is quite stressful. As the duration of diabetes increases and comorbid conditions like kidney, eye and heart disease set in, it becomes tougher. (1/5)
Mathew John retweeted
Same medicine. ₹4 crore a year vs ₹2.5 lakh a year. 💔
A helpless mom came to me with her child, who has Allan-Herndon-Dudley syndrome (MCT8 deficiency). It was very painful to see them so helpless. I tried to find a solution as if it were my own child. I couldn't rest otherwise.
Tiratricol wasn't available in India. Dr Santosh and I wrote to doctors. Dr Praveen and others directed us to the Erasmus team, who did the trials for Tiratricol. After many emails, they suggested Egetis Therapeutics might be able to support the child. I teared up. But our happiness was short-lived: Egetis said it could not give us the medicine.
I wrote to many journalists. I posted on Instagram and tagged the PM. Someone told me Tiratricol was available in Germany. The mother bought it, paying ₹12 lakh for just one month. That's impossible to keep up for life, for this child or for the five other children with the same condition under Dr Praveen's care at CMC Vellore.
Finally, Toufiq, a senior journalist, wrote about it, and it reached the Pharmaceutical Accountability Foundation in the Netherlands. They said Tiratricol can be made available at ₹2.5 lakh per child per year, against ₹4 crore per child per year by Egetis!
I raised funds, and the Pharmaceutical Accountability Foundation raised funds. Now 7 children are getting the medicine free of cost for one whole year. (The 7th child was added after my Instagram post.) 🙏
Thank you to Access to Medicines India and Organization for Rare Diseases India for their important role, and to geneticist Dr Kishore, who helped us reach the diagnosis.
India can compound the Active Pharmaceutical Ingredient here and make it available to every child with this condition at a reasonable cost.
👉 Please tag @narendramodi @JPNadda @MoHFW_INDIA
People of India, you can make it happen! Please share. 🙏
All the paediatricians, endocrinologists, paediatric endocrinologists, and paediatric neurologists, if you are currently caring for a child with confirmed or suspected MCT8 deficiency, please share the details below. Our team may contact you for further clinical information and coordination regarding diagnosis, treatment and access to tiratricol.
Please do not upload or share unnecessary patient-identifying information at this stage.
docs.google.com/forms/d/e/1F…
#AllanHerndonDudley #MCT8Deficiency #Tiratricol #Triac #Emcitate #RareDiseases #RareDiseaseIndia #AccessToMedicines #PharmaHijack #ChildHealth
Mathew John retweeted
A 72 year old man in Guntur got a knee replacement in June 2025. Within a month, the artificial joint was infected by Pseudomonas aeruginosa, a bacterium resistant to a wide range of antibiotics, including carbapenems.
Months of washouts, a spacer exchange, an arthroscopy and weeks of intravenous antibiotics followed. By Dec, his pain was 9/10. The infection kept returning. Doctors judged further surgery unsuitable given his age and condition.
The team then tried bacteriophages: viruses that infect specific bacteria.
For those interested in the science, this is where the work gets interesting....
Dr Sutharsan Govindarajan's phage lab at SRM University-AP tested the patient's own bacterial isolate against a panel of phages. 3 were selected and genome-sequenced.
In lab tests, each phage alone initially killed bacteria, but this strain subsequently regrew. The 3 phage cocktail suppressed that regrowth.
The cocktail was delivered into the infected knee through a drainage tube over 10 days. The antibiotic colistin was given alongside from day 2. Lab tests had shown that the combination worked better against this strain than either treatment alone.
- On day 6, colistin was stopped after kidney function worsened. The phage treatment continued.
- By day 10, tests of the joint fluid no longer detected the resistant bacterium. Pain had fallen from 9 to 2-3, and the man could walk independently again. His inflammation marker returned to normal a few days after treatment ended.
- At 6 months, he remained antibiotic-free with no recurrence reported. A joint-fluid culture in June 2026 showed no growth of the pathogen.
The clinical team was led by Dr Kalyan Chakravarthy Koganti at Samishta Hospital (SHRI), Guntur. The authors describe this as, to their knowledge, India's 1st reported successful phage treatment of a carbapenem-resistant prosthetic joint infection.
Bharat is rising. 🙏🙏
Source: B. Sivaraj et al., "Adjunctive Phage Therapy for Carbapenem-Resistant Pseudomonas aeruginosa (CRPA) Prosthetic Knee Joint Infection in India: A Case Report", IJID Regions (2026), available online 14 October. DOI: 10.1016/j.ijregi.2026.101047.
Photo 1: Dr Kalyan Chakravarthy Koganti and the research team. (Credit: T. Vijaya Kumar / The Hindu.)
Photo 2: The actual paper's figure, including the patient's before/after knee photos, antibiotic-resistance results and recovery timeline. via Sivaraj et al., IJID Regions (2026), DOI: 10.1016/j.ijregi.2026.101047.
Mathew John retweeted
Highlighting CMC Vellore's contribution to the fields of #InfectiousDiseases & #GlobalHealth, Prof. George M. Varghese, Dept of Infectious Diseases, CMC Vellore, has been elected President of the Royal Society of Tropical Medicine and Hygiene (RSTMH).
Founded in 1907, @RSTMH is a global, multidisciplinary organisation dedicated to advancing #TropicalMedicine and global health through #research, knowledge-sharing and international collaboration.
ബഹുമാനപ്പെട്ട @vdsatheesan sir. തിരുവനന്തപുരത്തെ പൊളിഞ്ഞ് നശിച്ച് കിടക്കുന്ന NH66 ശരിയാക്കാൻ നിങ്ങളെക്കൊണ്ട് എന്തെങ്കിലും ചെയ്യാൻ സാധിക്കുമോ? ഒരു വർഷത്തിലേറെയായി ഒരു പണിയും നടക്കുന്നില്ല. ദുരിതം അനുഭവിച്ച് മടുത്തു. @UDFKeralam_
Mathew John retweeted
My dear friends, please, I hope to demand your absolute attention to this matter:
In 2018, my junior from St. John’s Medical College, Bengaluru, Dr. Randall Sequeira (middle in the pic), trekked up a steep, bauxite-rich plateau in Odisha to hold a monsoon health camp in the indigenous Kutiya Kondh village of Kutrumali.
In a piece he wrote then titled "Kutrumali’s Demons," Randall described sleeping under a dripping school roof in freezing fog, borrowing utensils from a local health worker to cook khichdi, and waking up at 6 AM to a line of tribal mothers. He wrote with heartbreak about treating malnourished toddlers with protruding bellies and visible ribs, listening to stories of stillbirths and chronic fevers, while noticing the shiny new solar lights installed by a mining conglomerate eyeing the aluminium ore beneath the villagers' feet.
Comparing his small medical team to hobbits sheltering in the night, Randall worried about the outside forces coming for that fragile village.
Randall stayed with the tribal/ adivasi community to serve them. After St. John’s and an MD in Internal Medicine from SMS Jaipur, he gave up every comfort of urban medicine to live in Kalahandi, recognizing that clinical prescriptions are meaningless when indigenous communities are stripped of their forests, water, and dignity.
On the night of October 16, Odisha police picked up Dr. Randall Sequeira and Dalit activist Laxman Naik at 11 PM from his home in Bhawanipatna. A gentle physician who has spent years trekking up hills to save tribal children is now locked in Rayagada sub-jail under frivolous but draconian charges (attempt to murder, dacoity), simply for standing with Adivasis peaceful protesting the mining of their sacred hills in Sijimali and Kutrumali.
thewire.in/rights/randall-se…
Odisha Govt. said it will cut down forests to connect tribal villages. But it was a way to bypass green laws and fast track London based Vedanta’s, and Adani's mining plans. Local organisations estimate that around 45 villages depend on these hills and would be affected.
reporters-collective.in/trc/…
The state has answered with repression rather than dialogue. In the last three years, at least 43 police cases have been filed and over a hundred Adivasis and Dalits, both women and men, have been incarcerated in Odisha jails. For example, from In March and april 2026, 8, 2026, to April 8, 2026, within one month, 24 people were sent to jail, 217 were made accused, and the number of “others” total 1,140. An activist who was not named in the original FIRs, but has since been implicated in about 12 cases, so that bail in one case is followed by arrest in another. This pattern of capture and releases have been used to crush rational dissent.
Dr. Randall understood that being a good doctor means understanding that prescriptions cannot compensate for the denial of land rights, that surgery cannot undo displacement and that no medical can substitute for the basic infrastructure a government has failed to provide.
thehindu.com/sci-tech/health…
To my fellow medical fraternity, and every citizen with a conscience: a kind physician who embodies the highest ethics of our profession is being criminalized to clear the way for bauxite mining. Please do not let his voice be buried in a sub-jail.
Amplify this, demand due process, and demand the immediate release. Please sign in this form to show solidarity: forms.gle/o2Rj2Uu3tXaoWu9dA
If anyone can help out in this situation please reach out to Medico Friend Circle - mfcindia.org/
Mathew John retweeted
Hafta sonu cumartesi ve pazar gününü acil koroner bypass ameliyatlarında geçirdikten sonra pazartesi günü bir iki rutin damar ameliyatlarımı yaptım. Tam bu akşam dinlenirim artık derken bir tanıdığım hastaya yapılan anjio sonrası acil koroner bypass ameliyatı gerekti. O akşam ameliyat, yoğun bakımda takip vs. derken gece 03’te eve gidebildim. Saat 05’te hastanın ilaçlara rağmen tansiyonunda düşme ve kan gazlarında bozulma olması üzerine hastaneye geri döndüm. Hastayı değerlendirip yeniden ameliyata aldım. Ameliyattan çıkış, diğer hastaların viziti derken poliklinikçi olduğum için 1,5 saatlik uykuyla saat 09.30’da poliklinik muayenesine başlayabildim. Bazı hastalar kendi açılarından muayeneye geç girdikleri veya geç geldiğim için söyleniyorlardı. Kimisi yorgun görünüyorsunuz deyip empati yapıyor, kimisi umursamıyordu bile. Yine bir kalp damar cerrahisi polikliniğinde toplam 90 hasta hizmet bekliyordu. Aklım yoğunbakımdaki hastadaydı ve ara ara tuvalete gider gibi yanına gidip gelirken ve de hiç bir hasta mağdur olmasın diye bilgisayarda geliş zamanına göre normal muayene ve sonuç göstermeye gelen hastalara sırayla bakarken; numaratör ile çağırdığım hastanın önünden genç bir kız içeri girdi. Benim sonuçlarıma bakar mısınız dedi. Bende sırayla bakıyorum şimdi çıkın ben sizi çağırınca girin, sonra karışıklık oluyor dedim. Israr edince çıkın ben çağrınca gireceksiniz diye tekrar ettim. Bunun üzerine sert bir şekilde kapıyı resmen çarparak dışarı çıktı. Hemen arkasından çıkıp kapı önünde bekleyen bu kızı sekreterime göstererek bu hastaya bakmayacağım, reddediyorum, nereye giderse gitsin dedim ve hasta bakmaya devam ettim. Sonradan oğluyla gelen bir kadın hastam, doktor bey iyi ki o kıza bakmadınız, iyi ki kapıyı çarpıp çıktığında sizin için söylediğini duymadınız dedi. Ne söyledi dedim, önce söylemek istemedi; ısrar edince sıkılarak size O. Ç. dedi dedi. Allahım biz ne yaptık ta veya ne oldu da hastalarımızla bu hale düştük diye düşündüm. Mesleki yaşantımın 41. yılında, hastanemin en yaş almışı değil en kıdemli ve deneyimli hekimi olarak bu günleri de görmüş oldum. 19 yaşında olduğunu öğrendiğim bir kız çocuğundan dolaylı da olsa böyle bir hakaret işitmiş olmuştum. Onun yetiştirilme ortamına mı üzülsem, ailesine mi üzülsem; sağlıkçılara bakış açısına mı üzülsem, sistemin aynı tarafta olması gereken hastalarımızla bizleri nasıl karşı karşıya getirdiğine mi üzülsem bilemedim. Bir uzmanın karşısına elini kolunu sallayarak, randevu sistemini delerek, başkalarının hakkını çiğneyerek babasının babası yaşındaki bir hekime saygısızlık yapmak nedir ya. Bizleri poliniklerde bu sistemi sürdürmek, müşteri memnuniyetini, pardon hasta memnuniyetini sağlamak için yılda 1 milyar üç yüz milyon poliklinik başvurusu ile öğünen bir sistemin parçası olmak zorunda olmaktan tüm hekimlerin ve sağlık çalışanlarının rahatsız olduğunu biliyorum. Umarım ki hastalarımıza insanca bakabileceğimiz, yeterli zaman ayırabileceğimiz; onların polikliniklere ortalama geliş sayılarının artması ile değil, azalması ile öğünülecek günler yakındır.
Mathew John retweeted
doctor’s duty is to treat patients, not to tolerate abuse and intimidation. When attendants aggressively confront a doctor and start filming her, walking away from an escalating situation is not ego. It is self-defence.
You cannot expect doctors to work under fear of assault and then lecture them about their duty when they try to protect themselves.
Patient safety matters. But doctor’s safety is a prerequisite for that.
Female Doctor Se Behas Hui, Injured Patients Ko Chhodkar Uthkar Chali Gayi! Budhwar raat Ambah Civil Hospital mein accident mein injured teen logon ka treatment chal raha tha. Parijanon ke mutabik, dressing ke baad unhone female doctor se patients ko dekhne ke liye kaha. Doctor ne patients ko unke paas lane ko kaha. Isi baat par behas hui aur female doctor allegedly uthkar wahan se chali gayi. Parijanon ne baad mein BMO se verbal complaint bhi ki. Doctor ka kaam patient ka treatment karna hota hai. Parijanon se behas hui toh uski saza injured patient ko kyun? Ego baad mein, patient ka treatment pehle.
Source : @ambahnews #viralvideo
Mathew John retweeted
Issue with most Indians when they come to govt hospital and their conduct with govt doctors is they confuse service with servility.
A doctor at a govt hospital is providing you service, he/she is NOT YOUR SERVANT.
Healthcare service is not hospitality service.
Mathew John retweeted
Hi!
Emergency Physician here.
First rule especially in Emergency/Casualty duty.
If the mob gets aggressive, don't argue, don't justify, don't get defensive.
Nobody will fight for you. Nobody will defend you.
Your family needs you. You need you.
Just walk away, save yourself first.
Female Doctor Se Behas Hui, Injured Patients Ko Chhodkar Uthkar Chali Gayi! Budhwar raat Ambah Civil Hospital mein accident mein injured teen logon ka treatment chal raha tha. Parijanon ke mutabik, dressing ke baad unhone female doctor se patients ko dekhne ke liye kaha. Doctor ne patients ko unke paas lane ko kaha. Isi baat par behas hui aur female doctor allegedly uthkar wahan se chali gayi. Parijanon ne baad mein BMO se verbal complaint bhi ki. Doctor ka kaam patient ka treatment karna hota hai. Parijanon se behas hui toh uski saza injured patient ko kyun? Ego baad mein, patient ka treatment pehle.
Source : @ambahnews #viralvideo
Mathew John retweeted
The man who cracked the biology behind Ozempic still works as a hospital doctor and made almost nothing, while the drug built on his discovery became the best-selling medicine on Earth.
His name is John Eng.
He worked at a Veterans Affairs hospital in the Bronx, treating diabetes patients all day and running experiments on the side. No big lab. No famous university behind him. Just a hospital bench and a question that would not leave him alone.
The question was about a lizard.
The Gila monster is a fat, slow desert lizard from Arizona. It eats maybe three or four times a year. That is not a typo. It can go months without a single meal and its blood sugar stays perfectly stable the entire time. No spikes. No crashes. A human who ate like that would be dead or in a coma. The lizard is fine.
In the early 1980s, some government researchers noticed that the venom of this lizard did something strange to the pancreas, the organ that controls blood sugar. They filed it away as a curiosity and moved on. Nobody chased it.
Eng chased it.
He could not exactly go catch a venomous lizard in the Bronx. So he did the only thing he could afford. He ordered dried, preserved Gila monster venom out of a mail-order catalog from a reptile supplier in Utah. It showed up in the post. He started pulling it apart to see what was inside.
In 1992 he found it. A molecule nobody had ever documented, hiding in the venom. He named it exendin-4.
Here is why it mattered.
Your own body makes a hormone that tells your pancreas to release insulin after you eat. It is called GLP-1. It works beautifully. There is just one problem. It falls apart in about two minutes. Your body destroys it almost as fast as it makes it, which makes it useless as a medicine. Scientists knew about it and kept hitting the same wall.
The lizard molecule did the exact same job. It walked up to the same door in your cells and opened it the same way. But it did not fall apart in two minutes. It kept working for hours. The lizard had evolved a version of the human hormone that survived. Nature had already solved the problem medicine was stuck on.
Eng knew what he was holding.
His own employer did not care. The VA refused to patent it, because a lizard diabetes drug did not count as a "veteran-specific" problem. So Eng paid for the patent himself. Out of his own pocket. A hospital doctor spending his own money to protect a discovery his bosses had shrugged at.
Then he went looking for a drug company to build it.
For three years, every door shut. A diabetes drug made from lizard spit sounded like a joke. Serious pharmaceutical people did not want their name on it. One scientist who watched it happen said Eng was completely frustrated, that none of the important people would even look at him.
In 1996 he pinned a poster to a wall at a diabetes conference and stood next to it. Most people walked past. One researcher from a small California company called Amylin stopped and actually read it. One month later they licensed his patent.
That poster became a drug called Byetta. The FDA approved it in 2005, thirteen years after Eng first pulled the molecule out of that mail-order venom. It was the first drug of its kind ever sold. A twice-a-day shot for diabetes, grown from the spit of a lizard that eats twice a year.
Byetta was the proof. It showed the whole world that this pathway worked in real humans. And once everyone could see it worked, the giants moved in.
A Danish company took the same idea and built a better version. Instead of copying the lizard, they modified the human hormone directly so it would survive in the body the way the lizard's did. That drug is semaglutide. You know it by its other names. Ozempic. Wegovy.
So no, Ozempic is not literally lizard venom. It is built from the human hormone. But nobody would have built it if a lizard in the desert had not proven the whole idea could work first, and if one Bronx doctor had not refused to let that proof die on a shelf.
In 2025 alone, that single family of drugs did over 48 billion dollars in sales. It has become the best-selling prescription medicine on the planet. Celebrities take it. Your neighbors take it. It is on every feed you scroll. People treat it like it appeared out of nowhere two years ago.
It did not. The door it walks through was found in lizard venom by a hospital doctor who bought his samples by mail.
Here is the part that should sit with you.
John Eng got paid for Byetta, the drug built directly from his lizard molecule. But Ozempic and Wegovy, the ones worth tens of billions, were built from the human hormone instead of his exendin-4. So he does not collect a cent from the biggest drug story in the world. The man who proved the whole thing was possible watches the boom from the outside.
Every person injecting themselves this week is using a door that a lizard evolved and a forgotten doctor refused to stop knocking on.
The molecule was always there. The lizard had it the whole time.
It just took one man who wouldn't stop asking why a monster in the desert never goes hungry.
A mammogram missed her cousin's breast cancer. By the time it was found it was too late, and she died.
About 6 months later a second woman in the same family was diagnosed. She died as well.
The woman watching this happen was an artificial intelligence researcher.
Her name is Geetha Manjunath.
She grew up in Bengaluru. She took her bachelor's degree in computer science at UVCE, then a master's and a doctorate at the Indian Institute of Science, where she was a gold medallist.
Her first job was at the Centre for Development of Advanced Computing, where she was part of the team that built India's first commercial supercomputer in the 1990s.
She spent 17 years at Hewlett Packard Labs as a principal research scientist. She then became a lab director at Xerox Research in India, heading their data analytics research.
Then the 2 deaths in her family happened, and she went and read about the disease.
What she found is worth knowing.
In India, roughly half the women diagnosed with breast cancer die of it. Her own words are blunt. Every alternate lady detected with breast cancer is dying.
The reason is almost never the treatment. It is that the disease is found too late.
Mammograms are the standard test. They use x-rays, they are expensive, they are uncomfortable, they need a large fixed machine, and there is a specific medical problem with them. In younger women the breast tissue is denser, and dense tissue and tumours both show up white on the scan. So the tumour can hide.
That is what happened to her cousin.
She started working on it in her spare time, on weekends, with a small team, while still employed.
The idea was to use thermal imaging instead. A cancer uses more energy than normal tissue and the blood flow around it increases, so the area is slightly warmer. A thermal camera can see that heat pattern from a distance, without touching the body and without any radiation.
The hard part is reading it. Heat patterns are messy. That is where her actual expertise came in. She trained machine learning software to interpret them.
Their first test was with a medical college in Manipal, using thermal images of 72 cancer patients.
It worked.
In 2016 she left her job and started a company with a former colleague, Nidhi Mathur. They called it Niramai, which stands for Non Invasive Risk Assessment with Machine Intelligence, and which in Sanskrit also means free from illness.
The test needs no radiation, no touch, no pain, and no one else in the room. It works on women of any age and any breast density. The equipment is portable, so it can be taken to villages.
More than 400,000 women have now been screened across over 250 locations in India. More than 2,000 cancers have been found.
The technology has regulatory clearance in the United States and in Europe. She holds 14 American patents.
She has one line she repeats.
Nobody needs to die of breast cancer, if you can catch it early enough.
Mathew John retweeted
Dr. Priyam here. Today, let me teach you how to interpret a Kidney Function Test (KFT) exactly how I do it as an Internal Medicine resident.
By the end, you won't have a single question left. And also KFTs aren't just about kidneys actually. Let me break it down.
Mathew John retweeted
If you have a tooth problem, you go to a Dentist because you trust their education.
If you want to build a house, you hire a Civil Engineer because you know they are qualified.
If you want to file your taxes, you go to a CA because you know they have the knowledge.
If you want to build a website, you hire a Software Developer because they have the skills.
But when it comes to the people who make laws, control taxes, and decide the future of our country... We don't even ask for the minimum qualification.
I believe no one should be allowed to become a politician without proper education, training, and a qualifying exam.
There should be a college.
There should be a degree.
There should be a national exam.
Before asking for our vote, every candidate should have to prove they understand the Constitution, economics, law, public administration, ethics, and governance.
Today, all you need is money, marketing, muscle power, or social media fame.
If every profession needs qualification, politics should be the first one.
MUST.
His name is Dinesh Thakur.
He gave up a safe, high paying job and spent eight years of his life fighting one of the largest drug companies in the country. He did it because he discovered that the medicines millions of people trusted were built on a lie.
He was a chemical engineer who had worked in America and come back to India for a senior role at Ranbaxy, then the biggest generic medicine maker in the country. It was a proud Indian company whose cheap medicines were sold across the world.
Not long after he joined, he was asked to look into the quality of the company's drugs. What he found frightened him.
The company was faking its test results. Medicines were being sold without being properly tested for whether they were safe, or whether they even worked. The data handed to regulators was simply invented.
These were not luxury goods. These were the tablets that sick people swallowed every day, trusting that they would heal them.
Thakur went to his own bosses with what he had found. Nothing changed. So he made a choice that cost him everything. He resigned, and he reported the company to the American drug regulators.
Then began eight long years. He handed over evidence, sat through investigation after investigation, and lived under the shadow of taking on a giant that had every reason to crush him.
In 2013, it ended. Ranbaxy admitted its guilt in an American court, pleaded guilty to seven serious crimes, and was made to pay one of the largest fines ever handed to a generic drug maker, five hundred million dollars.
Because one man refused to look away, the way the world checks the safety of its medicines was changed for good.
He had a comfortable life and a good salary. He gave it all up so that the medicine in a stranger's hand could be trusted.
Mathew John retweeted
People often ask, "What have you achieved in your life?"
The answer is in this video.
My writ petition, W.P. No. 27356 of 2019, led to action against around 300 illegal brick kilns in Coimbatore. Today, large herds of elephants are reclaiming their habitat. Black leopards and even tigers are returning to these landscapes.
There can be no greater reward than witnessing nature heal itself. These are the moments that will make me dance all the way to my grave with a smile.
@tnforestdept @RvRanjithtvk @CMOTamilnadu
Mathew John retweeted
Picture this: It's 2005 in Hyderabad, the pharmaceutical capital of India. A former CTO who just watched his previous company get acquired for $550 million decides to bet everything on a radical idea—build a pharma company that treats African AIDS patients with the same quality standards as American cancer patients. No shortcuts. No "good enough for emerging markets." Just world-class chemistry at prices the developing world could afford.
That man was Dr. Satyanarayana Chava, and his company, Laurus Labs, would go on to become the world's largest third-party supplier of antiretroviral APIs, commanding 50% of the global market for key HIV drugs. Today, with a market cap north of ₹82,500 crore ($5.5 billion), Laurus has transformed from that single-minded API startup into an integrated pharmaceutical powerhouse spanning drug discovery to commercial manufacturing.
However, what makes this story remarkable is that, unlike the typical Indian pharma playbook of reverse-engineering expired patents and competing on price, Laurus built its empire on original chemistry.
Half of its 7000 employees work in R&D. The company holds over 300 patents. And in an industry where "Made in India" often meant a "cheaper alternative," Laurus supplies ingredients to nine of the ten largest generic pharmaceutical companies globally.
Src – empor top , no reco
Happy to share that the cover artwork, "Pink and Beyond," designed by the COPE Unit at ICMR-NINE, has been featured on the cover of The Lancet Regional Health – Southeast Asia June 2026 issue.
Article Link:
thelancet.com/journals/lanse…
#BreastCancer #CancerSurveillance #icmrnine
Mathew John retweeted
I am deeply honored to be conferred the *“Champions of Change Award 2026”* for Public Health Service by Lions Club International at Chennai.I extend my heartfelt thanks to International President AP Singh Ji and Shyamji Malpani for their gracious recognition and inspiration. This award strengthens my resolve to continue serving the community with greater commitment.
Mathew John retweeted
Forbes India #WPower2026: A Forbes India list celebrating the country's top self-made women
Dr. Sivaranjani Santosh is an Indian paediatrician and public health advocate based in Hyderabad who is known for her work in preventive healthcare and child health awareness.
Dr Santosh gained national attention for her long campaign against the misleading marketing of sugary drinks as oral rehydration solutions (ORS). Her efforts pushed regulators to tighten rules around the use of the term “ORS” on beverage labels in India.
She is presented the award by Suveen Sinha, editor, Forbes India.
Photos: Mexy Xavier / Swapnil Sakhare for Forbes India






























